EA201400031A1 - Стабильные составы на основе фермента, разрушающего хиалуронан - Google Patents
Стабильные составы на основе фермента, разрушающего хиалуронанInfo
- Publication number
- EA201400031A1 EA201400031A1 EA201400031A EA201400031A EA201400031A1 EA 201400031 A1 EA201400031 A1 EA 201400031A1 EA 201400031 A EA201400031 A EA 201400031A EA 201400031 A EA201400031 A EA 201400031A EA 201400031 A1 EA201400031 A1 EA 201400031A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- enzyme
- hyaluronane
- destructing
- compositions based
- stable compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 102000004190 Enzymes Human genes 0.000 title abstract 3
- 108090000790 Enzymes Proteins 0.000 title abstract 3
- 230000000593 degrading effect Effects 0.000 abstract 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 abstract 2
- 229940099552 hyaluronan Drugs 0.000 abstract 2
- 229920002674 hyaluronan Polymers 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161520962P | 2011-06-17 | 2011-06-17 | |
| PCT/US2012/042816 WO2012174478A2 (en) | 2011-06-17 | 2012-06-15 | Stable formulations of a hyaluronan-degrading enzyme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201400031A1 true EA201400031A1 (ru) | 2014-07-30 |
Family
ID=46513830
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201400031A EA201400031A1 (ru) | 2011-06-17 | 2012-06-15 | Стабильные составы на основе фермента, разрушающего хиалуронан |
| EA201501068A EA033472B1 (ru) | 2011-06-17 | 2012-06-15 | Композиция для стабилизации гиалуронидазы и ее применение |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201501068A EA033472B1 (ru) | 2011-06-17 | 2012-06-15 | Композиция для стабилизации гиалуронидазы и ее применение |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2720712B1 (https=) |
| JP (3) | JP2014518216A (https=) |
| KR (2) | KR101874401B1 (https=) |
| CN (2) | CN105797140B (https=) |
| AU (2) | AU2012271359B2 (https=) |
| BR (1) | BR112013032396A2 (https=) |
| CA (1) | CA2839511C (https=) |
| EA (2) | EA201400031A1 (https=) |
| ES (1) | ES2566549T3 (https=) |
| IL (1) | IL229749A0 (https=) |
| MX (1) | MX340172B (https=) |
| NZ (2) | NZ618331A (https=) |
| WO (1) | WO2012174478A2 (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102596175A (zh) | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
| US20130011378A1 (en) | 2011-06-17 | 2013-01-10 | Tzung-Horng Yang | Stable formulations of a hyaluronan-degrading enzyme |
| WO2013102144A2 (en) | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| AU2013366692B2 (en) | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| TWI780236B (zh) * | 2013-02-04 | 2022-10-11 | 法商賽諾菲公司 | 胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物 |
| ES2804719T3 (es) * | 2013-02-04 | 2021-02-09 | Sanofi Sa | Formulaciones farmacéuticas estabilizadas de análogos de insulina y/o derivados de insulina |
| TW201605489A (zh) * | 2013-10-25 | 2016-02-16 | 賽諾菲公司 | 賴谷胰島素（ｉｎｓｕｌｉｎ ｇｌｕｌｉｓｉｎｅ）的穩定調配物 |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| MX2016008979A (es) | 2014-01-09 | 2016-10-04 | Sanofi Sa | Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina. |
| JP6562902B2 (ja) * | 2014-03-28 | 2019-08-21 | テルモ株式会社 | 生体血管内血液置換用液体、生体血管内血液置換用液体製剤およびプレフィルドシリンジ |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| CN104095871A (zh) * | 2014-07-10 | 2014-10-15 | 青岛蔚蓝生物股份有限公司 | 一种含盐酸林可霉素与硫酸大观霉素的兽用注射液 |
| AU2015289619C1 (en) | 2014-07-16 | 2021-01-07 | New York University | Use of hyaluronidase for treatment of muscle stiffness |
| TW201630622A (zh) * | 2014-12-16 | 2016-09-01 | 美國禮來大藥廠 | 速效胰島素組合物 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CN105018457A (zh) * | 2015-07-20 | 2015-11-04 | 宁波美成生物科技有限公司 | 虫荧光素酶稳定剂 |
| CN114835793A (zh) * | 2015-11-16 | 2022-08-02 | Ubi蛋白公司 | 用于延长蛋白质半衰期的方法 |
| JP6798030B2 (ja) | 2016-09-06 | 2020-12-09 | シンファー ティアン−リー ファーマシューティカル カンパニー リミテッド（ハンツォウ）Ｓｉｎｐｈａｒ Ｔｉａｎ−Ｌｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｃｏ．， Ｌｔｄ． （Ｈａｎｇｚｈｏｕ） | 皮膚ケアおよび／または創傷治癒促進における松塊抽出物およびその有効成分の使用 |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| CN108070532A (zh) * | 2016-11-16 | 2018-05-25 | 福建力多利生物科技有限公司 | 一种生产葡萄糖氧化酶的方法 |
| WO2019050749A1 (en) * | 2017-09-08 | 2019-03-14 | Eli Lilly And Company | PHARMACEUTICAL COMBINATIONS COMPRISING INSULIN AND AT LEAST ONE AGENT SELECTED AMONG MELOXICAM, BROMFENAC SODIUM, ACETYLSALICYLIC ACID, SALICYLIC ACID AND PARACETAMOL |
| CN107918020B (zh) * | 2017-11-15 | 2019-01-01 | 浙江夸克生物科技有限公司 | 中性粒细胞明胶酶相关脂质运载蛋白测定试剂盒 |
| MX2020009824A (es) | 2018-07-25 | 2021-01-15 | Alteogen Inc | Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma. |
| WO2020190591A1 (en) * | 2019-03-15 | 2020-09-24 | Eli Lilly And Company | Preserved formulations |
| KR102650991B1 (ko) | 2019-03-25 | 2024-03-27 | (주)알테오젠 | 인간 히알루로니다제 ph20의 변이체와 약물을 포함하는 피하투여용 약학 조성물 |
| CN110592056A (zh) * | 2019-09-19 | 2019-12-20 | 昆明理工大学 | 噬菌体裂解酶复合粉剂及其制备方法和应用 |
| CN110713983B (zh) * | 2019-11-04 | 2022-06-10 | 深圳市体内生物医药科技有限公司 | 一种表达透明质酸酶的免疫细胞及其应用 |
| CN120699939A (zh) * | 2020-01-23 | 2025-09-26 | 阿特根公司 | 具有改善的稳定性的新玻尿酸酶变体及含有其的药物组合物 |
| US12221638B2 (en) | 2020-08-07 | 2025-02-11 | Alteogen Inc. | Method for producing recombinant hyaluronidase |
| JP2024501029A (ja) | 2020-12-28 | 2024-01-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｐｄ１／ｐｄ－ｌ１抗体の皮下投与 |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| JP2024501721A (ja) * | 2020-12-30 | 2024-01-15 | 上海宝済薬業股▲ふん▼有限公司 | 組換えヒトヒアルロニダーゼ製剤およびその用途 |
| JP2024541973A (ja) * | 2021-10-29 | 2024-11-13 | アルテオジェン・インコーポレイテッド | ヒトヒアルロニダーゼｐｈ２０及び薬物を含む医薬組成物 |
| CN115820766B (zh) * | 2021-12-28 | 2024-11-12 | 华熙生物科技股份有限公司 | 一种酶法制备软骨素寡聚糖的方法及软骨素寡聚糖组合物 |
| KR20250022071A (ko) | 2022-06-02 | 2025-02-14 | 브리스톨-마이어스 스큅 컴퍼니 | 항체 조성물 및 이의 이용 방법 |
| CN120475959A (zh) * | 2022-12-23 | 2025-08-12 | 韩美药品株式会社 | 包含免疫活性白细胞介素2类似物缀合物的制剂 |
| KR102554775B1 (ko) * | 2023-02-07 | 2023-07-12 | 한국코러스 주식회사 | 히알루로니다제의 안정화제 및 이를 포함하는 히알루로니다제 제형 |
| CN117243852A (zh) * | 2023-11-01 | 2023-12-19 | 华熙生物科技股份有限公司 | 一种皮肤外用组合物及其用途 |
| CN119074669B (zh) * | 2024-06-21 | 2025-04-18 | 邢珺月 | 一种靶向缓解化疗心脏毒性的纳米酶及其制备方法和应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
| EP0162007A1 (de) * | 1984-04-18 | 1985-11-21 | Geriaco AG | Stabiles, lagerungsfähiges Insulinpräparat zur Behandlung von Akne vulgaris |
| EP0250119A3 (en) * | 1986-06-20 | 1990-04-18 | Vasocor | Atherosclerotic anti-idiotype antibody immunoassay and reagents |
| US5122614A (en) | 1989-04-19 | 1992-06-16 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| US6093563A (en) | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5747027A (en) | 1995-04-07 | 1998-05-05 | The Regents Of The University Of California | BH55 hyaluronidase |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| US6610292B2 (en) * | 1995-11-22 | 2003-08-26 | Ista Pharmaceuticals, Inc. | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
| ES2230727T3 (es) | 1997-11-12 | 2005-05-01 | Alza Corporation | Procedimiento de administracion dermal de polipeptidos. |
| US6669663B1 (en) * | 1999-04-30 | 2003-12-30 | Medtronic, Inc. | Closed loop medicament pump |
| US6563022B2 (en) * | 1999-07-05 | 2003-05-13 | Toyo Boseki Kabushiki Kaisha | Cotton plants with improved cotton fiber characteristics and method for producing cotton fibers from these cotton plants |
| CA2394980C (en) | 1999-12-22 | 2008-05-13 | Shearwater Corporation | Sterically hindered derivatives of water soluble polymers |
| DK1282599T3 (da) * | 2000-05-19 | 2006-07-31 | Alcon Inc | Disulfidderivater, der er egnede til behandling af allergiske sygdomme |
| US6902548B1 (en) * | 2001-03-19 | 2005-06-07 | Ed Schuler | Use of Streptomyces hyalurolyticus enzyme in ophthalmic treatments |
| US20030125234A1 (en) * | 2001-12-11 | 2003-07-03 | Middaugh Charles Russell | Alteration of protein stability |
| BRPI0407882B1 (pt) | 2003-02-26 | 2021-07-27 | Nektar Therapeutics | Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação |
| NZ542873A (en) | 2003-03-05 | 2008-07-31 | Halozyme Inc | Soluble, neutral-active hyaluronidase activity glycoprotein (sHASEGP) that is produced with high yield in a mammalian expression system by introducing nucleic acids that lack a narrow region encoding amino acids in the carboxy terminus of the human PH20 cDNA |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| CA2521940C (en) * | 2003-04-23 | 2010-01-26 | Latrobe University | Insect chymotrypsin and inhibitors thereof |
| US7279457B2 (en) | 2004-03-12 | 2007-10-09 | Biodel, Inc. | Rapid acting drug delivery compositions |
| WO2005095625A1 (en) * | 2004-03-31 | 2005-10-13 | Hexima Ltd | Arabinogalactan protein compositions and methods for fostering somatic embryogenic competence |
| WO2005118799A1 (en) * | 2004-04-15 | 2005-12-15 | Ista Pharmaceuticals, Inc. | Ovine hyaluronidase |
| WO2007047242A2 (en) * | 2005-10-14 | 2007-04-26 | Soll David B | Ophthalmic surgical irrigating solutions containing hyaluronidase |
| JP2009512709A (ja) * | 2005-10-20 | 2009-03-26 | エムディーアールエヌエー，インコーポレイテッド | 速効型インスリンの経鼻投与 |
| WO2008016729A1 (en) * | 2006-08-04 | 2008-02-07 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
| IL186598A0 (en) * | 2007-10-11 | 2008-11-03 | Mohammad Abdulrazik | Composition and method for the treatment or prevention of glaucoma and ocular hypertension |
| SI4269578T1 (sl) | 2008-03-06 | 2024-07-31 | Halozyme, Inc. | Sestava topne hialuronidaze |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
| EA022752B1 (ru) | 2008-12-09 | 2016-02-29 | Галозим, Инк. | Длинные растворимые полипептиды рн20 и их использование |
| CN102596175A (zh) * | 2009-07-06 | 2012-07-18 | 赛诺菲-安万特德国有限公司 | 含有甲硫氨酸的水性胰岛素制备物 |
| HUE028832T2 (en) | 2009-09-17 | 2017-01-30 | Baxalta Inc | Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation |
| CA2839512C (en) * | 2011-06-17 | 2018-01-02 | Halozyme, Inc. | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme |
| WO2013102144A2 (en) * | 2011-12-30 | 2013-07-04 | Halozyme, Inc. | Ph20 polypeptede variants, formulations and uses thereof |
-
2012
- 2012-06-15 NZ NZ618331A patent/NZ618331A/en not_active IP Right Cessation
- 2012-06-15 NZ NZ717728A patent/NZ717728A/en not_active IP Right Cessation
- 2012-06-15 MX MX2013014923A patent/MX340172B/es active IP Right Grant
- 2012-06-15 WO PCT/US2012/042816 patent/WO2012174478A2/en not_active Ceased
- 2012-06-15 CN CN201610243096.3A patent/CN105797140B/zh active Active
- 2012-06-15 EA EA201400031A patent/EA201400031A1/ru unknown
- 2012-06-15 KR KR1020177027130A patent/KR101874401B1/ko not_active Expired - Fee Related
- 2012-06-15 EP EP12735366.2A patent/EP2720712B1/en active Active
- 2012-06-15 ES ES12735366.2T patent/ES2566549T3/es active Active
- 2012-06-15 EA EA201501068A patent/EA033472B1/ru not_active IP Right Cessation
- 2012-06-15 KR KR1020147001375A patent/KR20140043438A/ko not_active Ceased
- 2012-06-15 BR BR112013032396A patent/BR112013032396A2/pt not_active IP Right Cessation
- 2012-06-15 JP JP2014516067A patent/JP2014518216A/ja active Pending
- 2012-06-15 AU AU2012271359A patent/AU2012271359B2/en not_active Ceased
- 2012-06-15 CA CA2839511A patent/CA2839511C/en active Active
- 2012-06-15 CN CN201280039713.8A patent/CN103974715A/zh active Pending
-
2013
- 2013-12-02 IL IL229749A patent/IL229749A0/en unknown
-
2016
- 2016-04-19 AU AU2016202472A patent/AU2016202472B2/en not_active Ceased
- 2016-10-12 JP JP2016200761A patent/JP6224802B2/ja active Active
-
2017
- 2017-06-06 JP JP2017111643A patent/JP2017197556A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ618331A (en) | 2016-04-29 |
| KR20140043438A (ko) | 2014-04-09 |
| NZ717728A (en) | 2016-04-29 |
| JP2014518216A (ja) | 2014-07-28 |
| IL229749A0 (en) | 2014-01-30 |
| EP2720712B1 (en) | 2016-03-02 |
| ES2566549T3 (es) | 2016-04-13 |
| WO2012174478A9 (en) | 2013-05-30 |
| JP2017197556A (ja) | 2017-11-02 |
| MX340172B (es) | 2016-06-28 |
| CA2839511C (en) | 2018-07-31 |
| WO2012174478A2 (en) | 2012-12-20 |
| EA033472B1 (ru) | 2019-10-31 |
| WO2012174478A3 (en) | 2013-04-11 |
| AU2012271359A1 (en) | 2014-01-09 |
| KR20170116173A (ko) | 2017-10-18 |
| JP2017036313A (ja) | 2017-02-16 |
| AU2012271359B2 (en) | 2016-05-19 |
| CN103974715A (zh) | 2014-08-06 |
| EA201501068A1 (ru) | 2016-07-29 |
| CA2839511A1 (en) | 2012-12-20 |
| AU2016202472B2 (en) | 2017-02-02 |
| CN105797140A (zh) | 2016-07-27 |
| EP2720712A2 (en) | 2014-04-23 |
| BR112013032396A2 (pt) | 2016-11-22 |
| JP6224802B2 (ja) | 2017-11-01 |
| CN105797140B (zh) | 2020-08-11 |
| MX2013014923A (es) | 2014-02-11 |
| KR101874401B1 (ko) | 2018-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201400031A1 (ru) | Стабильные составы на основе фермента, разрушающего хиалуронан | |
| CY1122532T1 (el) | Παραλλαγες πολυπεπτιδιου ρη20, σκευασματα και χρησεις αυτων | |
| AU2018256640A1 (en) | Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives | |
| MX2016008448A (es) | Conjugados de var2csa-farmaco. | |
| MX384253B (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica | |
| MX361862B (es) | Composiciones y métodos que comprenden variante de enzima lipolítica. | |
| AR087745A1 (es) | Composiciones y metodos que comprenden una variante de enzima lipolitica | |
| EA201301018A1 (ru) | Режимы дозирования для лечения болезни фабри | |
| EP2569330A4 (en) | CHLOROTOXIN VARIANTS AND CONJUGATES AND METHOD OF USE THEREOF | |
| WO2014025771A3 (en) | Methods and compositions for inactivating enveloped viruses | |
| EP2558124A4 (en) | POLYSACCHARID COMPOSITIONS AND METHOD FOR USE THEREOF FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH PRECURSOR CELL MOBILIZATION | |
| MX2019009229A (es) | Novedosas variantes enzimaticas que degradan la nicotina. | |
| EP3878445A3 (en) | Acamprosate formulations, methods of using the same, and combinations comprising the same | |
| MY188821A (en) | Pull-on absorbent article | |
| EP2575452A4 (en) | ANTIMICROBIAL COMPOSITIONS | |
| ZA201805648B (en) | Targeted therapeutic lysosomal enzyme fusion proteins, associated formulations and uses thereof | |
| PH12014500054A1 (en) | Formulations that stabilize proteins | |
| CY1119064T1 (el) | Ινωδολυτικες συνθεσεις οι οποιες περιεχουν βρωμελαϊνη και ναττοκιναση για την προληψη και αγωγη φλεβοθρομβωτικων καταστασεων | |
| AU2011365688A8 (en) | Peptides with antimicrobial activity, drug compositions for the prophylaxis and treatment of animals, compositions for the prophylaxis and treatment of plants, uses of said peptides, and uses of Paenibacillus elgii ourofinensis extract | |
| HK1246653A1 (zh) | 奥那司酮延长释放组合物和方法 | |
| IN2015MN00102A (https=) | ||
| MX2013005699A (es) | Composiciones de interferon-beta estables conservadas. | |
| TR201203087A2 (tr) | Seftibüten ve klavulanik asit formülasyonları. | |
| TR201203085A2 (tr) | Sefetamet ve klavulanik asit içeren bileşimler. | |
| TR201203086A2 (tr) | Sefiksim ve klavulanik asit içeren farmasötik dozaj formu. |